非维生素K拮抗剂口服抗凝药用于房颤合并既往消化道出血患者
经逆概率治疗加权平衡协变量后,NOAC组缺血性卒中、大出血及复合结局风险均低于华法林组。
要点
- 房颤合并既往消化道出血患者中,NOAC较华法林降低缺血性卒中风险(加权HR 0.608)。
- NOAC较华法林降低大出血风险(HR 0.731)及复合结局风险(HR 0.661)。
- NOAC在所有次要结局(致死性事件)上均显示较华法林更大的风险降低。
核心结论
- 在房颤合并既往消化道出血患者中,NOAC与华法林相比与更低的缺血性卒中和大出血风险相关。
研究设计与样本
- 采用逆概率治疗加权法平衡协变量,主要结局为缺血性卒中、大出血及复合结局。
主要发现
- 从既往消化道出血至启动口服抗凝药的平均时间为3.1±2.6年。
- 加权后基线特征平衡:平均年龄72岁,男性56.8%,平均CHA2DS2-VASc评分3.7。
- NOAC组较华法林组缺血性卒中风险降低(加权HR 0.608,95%CI 0.543-0.680)。
- NOAC组较华法林组大出血风险降低(HR 0.731,95%CI 0.642-0.832)。
- NOAC组较华法林组复合结局风险降低(HR 0.661,95%CI 0.606-0.721)。
临床怎么用
- 对于房颤合并既往消化道出血的患者,可考虑优先选用NOAC而非华法林以降低缺血性卒中及大出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Limited data support the benefits of non-vitamin K oral anticoagulants (NOACs) among atrial fibrillation patients with prior gastrointestinal bleeding (GIB). We aimed to evaluate the effectiveness and safety of NOACs compared with those of warfarin among atrial fibrillation patients with prior GIB. METHODS: Oral anticoagulant-naive individuals with atrial fibrillation and prior GIB between January 2010 and April 2018 were identified from the Korean claims database. NOAC users were compared with warfarin users by balancing covariates using the inverse probability of treatment weighting method. The primary outcomes were ischemic stroke, major bleeding, and the composite outcome (combined ischemic stroke and major bleeding). Fatal events from each outcome were evaluated as secondary outcomes. RESULTS: A total of 42 048 patients were included (24 781 in the NOAC group and 17 267 in the warfarin group). The mean time from prior GIB to the initiation of oral anticoagulant was 3.1±2.6 years. After inverse probability of treatment weighting, baseline characteristics were balanced between the two groups (mean age, 72 years; men, 56.8%; and mean CHA2DS2-VASc score, 3.7). Lower risks of ischemic stroke, major bleeding, and the composite outcome were associated with NOAC use than with warfarin use (weighted hazard ratio, 0.608 [95% CI, 0.543-0.680]; hazard ratio, 0.731 [95% CI, 0.642-0.832]; and hazard ratio, 0.661 [95% CI, 0.606-0.721], respectively). For all secondary outcomes, NOACs showed greater risk reductions compared with warfarin. CONCLUSIONS: NOACs were associated with lower risks of ischemic stroke and major bleeding than warfarin among atrial fibrillation patients with prior GIB.
引用
- Kwon S, Lee SR, Choi EK, et al. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Prior Gastrointestinal Bleeding. Stroke. 2021. PMID: 33412904. doi:10.1161/STROKEAHA.120.030761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。